New targeted therapy shows promise for leukemia patients with hidden cancer cells
NCT ID NCT03441061
First seen Feb 21, 2026 · Last updated Jun 10, 2026 · Updated 13 times
Summary
This study tests a drug called inotuzumab ozogamicin in 40 adults with B-cell acute lymphocytic leukemia who have minimal residual disease (small numbers of cancer cells left after treatment). The drug is an antibody that delivers a toxin directly to cancer cells. The goal is to see if it can prevent the cancer from coming back. Participants receive the drug intravenously, and researchers monitor side effects and how long they stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.